Innoviva 配当と自社株買い
配当金 基準チェック /06
Innoviva現在配当金を支払っていません。
主要情報
0%
配当利回り
0.7%
バイバック利回り
| 総株主利回り | 0.7% |
| 将来の配当利回り | n/a |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | 0% |
最近の配当と自社株買いの更新
Recent updates
分析記事 • Nov 13
Innoviva's (NASDAQ:INVA) Solid Profits Have Weak Fundamentals
Innoviva, Inc. ( NASDAQ:INVA ) just reported some strong earnings, and the market reacted accordingly with a healthy...分析記事 • Nov 12
Innoviva, Inc.'s (NASDAQ:INVA) Shares Bounce 26% But Its Business Still Trails The Market
Innoviva, Inc. ( NASDAQ:INVA ) shareholders would be excited to see that the share price has had a great month, posting...分析記事 • Sep 11
We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Aug 09
Innoviva, Inc. Just Recorded A 54% EPS Beat: Here's What Analysts Are Forecasting Next
NasdaqGS:INVA 1 Year Share Price vs Fair Value Explore Innoviva's Fair Values from the Community and select yours A...分析記事 • Jun 23
Innoviva, Inc.'s (NASDAQ:INVA) Low P/S No Reason For Excitement
Innoviva, Inc.'s ( NASDAQ:INVA ) price-to-sales (or "P/S") ratio of 3.6x might make it look like a buy right now...Seeking Alpha • Jun 08
Innoviva: A Riddle Wrapped In A Mystery Inside An Enigma
Summary Innoviva's diversified model blends royalty streams from GSK respiratory products with growing proprietary specialty therapeutics, driving revenue and operational income growth. Recent Q1 results showed strong operational net income and revenue growth, despite non-cash investment write-downs impacting GAAP results. The balance sheet has seen cash and marketable securities increase by just over $140 million over the past year. Innovia, Inc. is a very complicated story but seems to merit a small 'watch item' holding for now. An updated analysis around Innoviva follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Feb 23
Innoviva: Underappreciated Strength In Hospital Therapeutics
Summary Innoviva's strong balance sheet and stable royalty income from GlaxoSmithKline provide a solid foundation for its shift to specialty therapeutics, presenting an asymmetric risk-reward profile. The company is transitioning from a royalty collector to an operator in specialty therapeutics, with significant growth in product sales, notably GIAPREZA and XACDURO. Key assets like Zevtera, an advanced-generation antibiotic, and a promising pipeline in infectious diseases, position Innoviva for potential market disruption and growth. Despite execution risks and financial pressures, Innoviva's undervalued metrics and ample cash reserves suggest significant upside if it successfully commercializes its infectious disease portfolio. Read the full article on Seeking Alpha分析記事 • Dec 19
Innoviva, Inc.'s (NASDAQ:INVA) Popularity With Investors Is Under Threat From Overpricing
There wouldn't be many who think Innoviva, Inc.'s ( NASDAQ:INVA ) price-to-earnings (or "P/E") ratio of 17.4x is worth...分析記事 • Jul 26
Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price
Innoviva, Inc.'s ( NASDAQ:INVA ) price-to-earnings (or "P/E") ratio of 6.3x might make it look like a strong buy right...Seeking Alpha • Jun 21
Innoviva: Potentially Overvalued
Summary Innoviva shares have increased by 25% in the past year, matching S&P 500 returns. Innoviva's financial snapshot shows revenue and net income growth, but interest expenses have increased significantly. Market assumptions suggest an optimistic growth rate of 14%, making INVA stock potentially overvalued. Read the full article on Seeking Alpha分析記事 • May 21
Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems
Innoviva, Inc.'s ( NASDAQ:INVA ) recent weak earnings report didn't cause a big stock movement. We think that investors...分析記事 • Feb 05
Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Nov 04
Is Innoviva (NASDAQ:INVA) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Mar 02
Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Sep 19
Innoviva Stock? Not Yet. Short Puts? Definitely.
Summary I think the problem of higher revenues and lower profits lingers, and I think there's risk in the recent acquisitions. That written, there is potential here. The problem is that the shares aren't as cheap as I'd like. Thankfully, the options market offers us a way to generate some decent risk adjusted returns. It’s been about 3.5 months since I wrote my latest cautious note about Innoviva Inc. (INVA), and in that time the shares have cratered an additional 20.5% against a loss of about 6.8% for the S&P 500. Much has happened since I last wrote about the business, so I thought I’d review the name again. For instance, they have made another acquisition, and they have reported earnings. I did well trading this stock in the past, so it’s time to review the name. After all, a stock trading at $12.40 is, by definition, less risky than the same stock when it’s trading at $15.60. Finally, I never tire of writing about big bank analyst mistakes, and Innoviva gives me the opportunity to do just that. Welcome to the thesis statement paragraph of the article. I’ve already hinted that this article is going to be filled with even more bragging than usual, so I can understand why you’d want to a way to glean the highlights of my thinking so you can then leave the article before being exposed to too much Doyle mojo. I think there are risks here, and I think the negative relationship between revenue and net income remain a perennial problem. That written, I’d be happy to buy this business at the right price, as I think the firm has a fairly decent moat, and I think there’s potential in the most recent acquisitions. The problem for me is that the shares aren’t objectively cheap enough. Thankfully the options market offers an alternative, and so I’ll be selling puts this week. This concludes my thesis statement. If you read on from here, that’s on you. I don’t want to read any complaints in the comments section about my self aggrandizement or the fact that I spell words like “flavour” properly or similar. Update Before getting into the financial analysis, recently the company presented at the Morgan Stanley 20th Annual Global Healthcare Conference, and I think that deserves commentary. Feel free to listen to that presentation yourselves, obviously, but if you choose to subject yourselves to this, I would recommend wearing headphones and setting the speed to 0.75x normal because the audio quality is similar to what you’d expect to hear if the conference were broadcast from inside of a deflated basketball. In case you don’t want to subject yourself to this experience, I’ll offer you what I consider to be the highlights from the presentation for your enjoyment and edification: The company expects to remain cash flow positive, and they’ve made some efforts to clean up the capital structure. In particular, they issued a $250 million convertible note that was used to pay off debt due this coming January. They took a loss of about $20.6 million to extinguish this debt. The outlook for Relvar/Breo and Anoro both look good. Even when the royalty streams for these products eventually run dry, the reality is that it’s challenging to get new products approved and onto the market. Thus, there’s a likely moat around these for some time to come. With the acquisition of Entasis and La Jolla, the company seems to be moving toward acquiring operating assets as opposed to royalty assets. The Morgan Stanley analyst noted the distinction between these two types of assets, and the challenges associated with moving from one type of asset to the other. The company believes that the acquisitions will be cash flow positive in relatively short order. La Jolla is cash flow positive as of now. While Entasis is pre-market, it’ll be possible to leverage the La Jolla hospital channel to sell into also. So, according to the company, the financial position has improved somewhat, and we’re going to review that claim below. I think the Morgan Stanley analyst is correct in suggesting that there’s risk associated with a royalty company buying operating companies. It’s generally also the case that even acquisitions that look good on paper have a nasty tendency to fail. Anyway, those were what I consider to be the highlights of the call, and I would urge you to listen to all 23 minutes of it if you’re so inclined. Financial Snapshot The most recent period continues a long, somewhat depressing trend at this firm, namely the disconnect between revenue and net income. Relative to the same period in 2021, the top line has grown about 6.4% but net income has plummeted by more than 90%. This happened in spite of a nice 29% reduction in interest expense. The chief culprits were the $19.6 million increase in R&D expenses, $8 million increase in G&A expenses, and a $20.6 million loss on debt extinguishment. The last of these won’t recur, obviously, but I think investors would be wise to gird themselves for the risk of a permanently higher cost structure here. In case you’re worried that I’m drawing a comparison between 2022 and a uniquely profitable year, fret no further, dear readers. During the presentation with Morgan Stanley, the company referenced the huge impact of the Covid pandemic, so I thought it’d be interesting to compare the current state to the pre-Covid state. When compared to the same period in 2019, revenue in 2022 is 66.2% higher, and net income is 76% lower. This is a perennial problem that I’ve been droning on about for years at this point. That said, about a month and a half after I put out my “avoid” recommendation on this stock, Goldman Sachs joined the party with a $16 price target, which represented an 8.7% upside from the then price of $14.72. Sadly the shares have gone the other way, obviously, but sooner or later Goldman’s relative optimism may pay off, so it may be worth buying the shares at the right price. Innoviva Financials (Innoviva investor relations) The Stock Welcome to the section of the article where I point out yet again what I consider to be screamingly obvious, namely that "the business" is quite a different thing from "the stock." If you read my stuff regularly for some reason, this isn't a shock to you. I feel a need to point this out because one of the more pernicious old adages that float around investing circles is that "we don't buy stocks, we buy businesses." No, we absolutely do not "buy businesses." We very much buy "stocks", and they are affected by forces that are in addition to the ups and downs of the firm. For instance, a stock may move up or down in price because of what an analyst has recently written about the business. Now, as the Goldman experience I wrote about above proves, this may not mean very much, but analyst activity is something. Also, the stock is very definitely affected by our collective views about the overall market, and stocks as an asset class. For example, given that the S&P has dropped about 6% since I wrote about this, a reasonable argument could be made to suggest that 30% of the drop in price is caused by people eschewing the “stock” asset class. It may be tiresome that your stock gets buffeted around by forces having very little to do with the company, but in my experience, this creates tremendous opportunity also. The only way to consistently make money trading stocks is to spot discrepancies between the crowd's view about a given company and subsequent results. This is the approach I’ve taken with Innoviva and it’s worked out pretty well. We want to go long a stock when the crowd becomes overly pessimistic, and we want to avoid stocks when the crowd becomes overly sanguine. This approach causes investors to miss out on some great gains in the short run, but I think it preserves the purchasing power of your capital over time, and that's really the name of the game in my view. I want to buy when the crowd is particularly pessimistic and I measure pessimism in a few ways, ranging from the simple to the more complex, and I publish some of those measures on this forum. On the simple side, I look at the ratio of price to some measure of economic value like earnings, free cash flow and the like. I want to see a stock trading at a discount to both the overall market and its own history. When last I reviewed Innoviva, I fretted about the fact that price to earnings and price to free cash flow were about 7.2 and 3.6 times respectively. The shares are either 38% more expensive or 17% cheaper depending on how you measure it per the following: Data by YCharts Since the shares are neither unambiguously cheap nor expensive, I’m on the horns of a dilemma. My tendency at the moment is to preserve capital, though I think there’s value here. I can either wait for shares to become more cheaply priced before buying, or I can earn some money today by selling put options on this stock. Those who read my stuff regularly know what I’m inclined to do. Options As Alternative In my previous article on this name, I pointed out that fully 13.7% of the $12.06 I had made trading this stock over the years has come from selling put options. I mentioned this for two reasons. First, and most importantly by far, writing about that gives me a chance to brag, and that’s never a bad thing (for me, anyway). Second, it reveals to readers the risk reducing, yield enhancing potential of these wonderful instruments. With that in mind, I recommend selling some more puts today. In particular, I’m a fan of the December Innoviva puts with a strike of $10 which are currently bid at $0.20. I like these because I enjoy the prospect of making 2% in three months. As my regulars know, I consider investments of this sort to be “win-win”, because the outcome is positive no matter what happens. If the shares remain above $10 in price between now and the third Friday of December, I’ll simply pocket the premium. If the shares drop below $10, I’ll be obliged to buy at a net price of $9.80, but I think that’d be a great entry price. It’s also much better than buying at the current market price. It's time, once again, to write about risk. It’s all well and good for a stranger on the internet to write about “win-win” trades, but if you’re going to trade these, you need to be made aware of the fact that this investment, like all investments, comes with risk. I consider the risks associated with these instruments to fall into two broad categories: the economic and the emotional.分析記事 • Sep 19
Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...分析記事 • Jun 16
Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jun 07
Continuing To Avoid Innoviva Inc.
The shares have collapsed since I took profits this past February. This put the company on my radar, as a cheap stock is definitionally safer than an expensive one. The problem is that the shares aren't cheap enough given the financial results the company has just posted. My track record here suggests that it's prudent to not "buy and forget" a given stock. It also demonstrates the relative power of selling put options.分析記事 • Mar 04
We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Feb 21
Taking Innoviva Winnings Off The Table, Again
I think Innoviva's recent financial results have been quite good in many ways. Both revenue and net income are materially higher than both 2020 and 2019. I think Innoviva management likely overpaid for the stock buyback, but this isn't the worst thing in the world, in my view. The worst thing is the valuation here. Last month's short puts are now even deeper out of the money, and the bid has collapsed as a result. So I'm selling INVA stock and maintaining my short put position.Seeking Alpha • Jan 15
Innoviva Inc.: Short Puts Are Compelling
The financial results so far in 2021 have been quite good in my estimation, and I don't think the share price reflects this reality. The shares are trading near levels that correspond to future decent returns, and for that reason I'll be taking a small position in the company. More compelling, in my view, are the short puts that I describe below.分析記事 • Oct 19
Is Innoviva (NASDAQ:INVA) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Seeking Alpha • Oct 16
Taking Profits In Innoviva Inc.
Results so far in 2021 have been impressive, with both revenue and net income much higher than the same periods in either 2020 or 2019. That said, the company fired a massive buyback program in the 2nd quarter and it seems the market yawned. This makes me wonder what will happen absent buybacks. I suggested investors also sell puts here. I take this opportunity to drone on yet again about the risk reducing, return-enhancing power of these options.分析記事 • Mar 30
These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Mar 04
Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Innoviva (NASDAQ:INVA) has had a rough month with its share price down 10%. However, a closer look at its sound...分析記事 • Jan 15
Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...分析記事 • Dec 25
These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Dec 04
Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?
With its stock down 9.7% over the past three months, it is easy to disregard Innoviva (NASDAQ:INVA). However, stock...決済の安定と成長
配当データの取得
安定した配当: INVAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: INVAの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Innoviva 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (INVA) | 0% |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Pharmaceuticals) | 2.1% |
| アナリスト予想 (INVA) (最長3年) | n/a |
注目すべき配当: INVAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: INVAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: INVA US市場において目立った配当金を支払っていません。
株主配当金
キャッシュフローカバレッジ: INVAが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 21:10 |
| 終値 | 2026/05/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Innoviva, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19
| アナリスト | 機関 |
|---|---|
| Jon Langenfeld | Baird |
| James Birchenough | Barclays |
| Patrick Trucchio | Berenberg |